Identify Targets More Effectively With Polly

Expand your pipeline of validated targets using harmonized biomedical data on Polly.

Multi-modal Data Is Critical for Target Validation

Poor target selection is the primary cause of clinical trial failure. To identify viable targets with a high threshold of certainty, your data pool needs to be scientifically robust, sufficiently large, and multi-modality. Therefore, having access to data that is integrated, harmonized, uniformly processed, and clean is critical.

How Polly Helps?

Build a Custom, ML-ready Atlas Specific to Your Research

Develop a customized Atlas with ML-ready data for bias-free target predictions.

Create a disease-specific Atlas comprising meticulously curated data enriched with critical metadata and engineered for seamless integration into target prediction models.

Enhance prediction accuracy and mitigate bias through model training with multi-modal, harmonized datasets.

Instill confidence in your predictions by combining consistently processed samples for robust results.

Derive Expression Signatures From Relevant Cohorts

Explore healthy and patient cohorts on Polly for a comprehensive molecular profiling of the disease being studied.

Conduct gene expression analysis to uncover differentially expressed signatures specific to the disease condition.

Identify potential candidate genes by assessing their druggability scores and cross-referencing with publicly available evidence.

Validate Identified Targets With Public Data

Cross-reference your results with published evidence using curated public data delivered on Polly.

Validate target reliability by meta-analyzing relevant studies on Polly.

Evaluate targets for sensitivity, specificity, and clinical utility with rigorous statistical analysis.

The Polly Difference

Accelerate Target ID

Achieve 4X faster target identification with Polly’s high-specificity prediction using multi-omics data.

Swift Target Validation

Speed up target validation with Polly's curated public evidence, reducing clinical trial risks.

Streamline Search

Cut your dataset search time by 75% with Polly's advanced search capabilities.

Case studies

Oncology Company Achieves ~80% Faster Gene Target ID & Validation

View Case Study

FAQs

What is Polly, and how does it support target identification?

Lorem ipsum dolor sit amet consectetur. Dictumst faucibus nibh imperdiet phasellus vitae ut sit. Ut eros amet massa tellus orci. Vestibulum ac arcu est nulla non eget nulla. Eget pulvinar eu ac mi cursus elementum neque. Massa nisl fringilla platea diam faucibus nullam. In lacus mauris nec ultrices. Ut accumsan leo adipiscing montes proin.

Polly is an AI-ready data platform that accelerates target identification by integrating and harmonizing multi-omics data. It provides machine-learning-ready datasets, enabling precise biomarker discovery and validation for drug development.

Why is multi-modal data crucial for effective target validation?

Lorem ipsum dolor sit amet consectetur. Dictumst faucibus nibh imperdiet phasellus vitae ut sit. Ut eros amet massa tellus orci. Vestibulum ac arcu est nulla non eget nulla. Eget pulvinar eu ac mi cursus elementum neque. Massa nisl fringilla platea diam faucibus nullam. In lacus mauris nec ultrices. Ut accumsan leo adipiscing montes proin.

Multi-modal data is crucial for effective target validation as it integrates diverse biological datasets such as genomics, transcriptomics, proteomics, and metabolomics to provide a comprehensive view of disease mechanisms. This approach enhances accuracy in identifying viable therapeutic targets, reducing clinical trial failures.

How does Polly ensure harmonized and uniformly processed biomedical data?

Lorem ipsum dolor sit amet consectetur. Dictumst faucibus nibh imperdiet phasellus vitae ut sit. Ut eros amet massa tellus orci. Vestibulum ac arcu est nulla non eget nulla. Eget pulvinar eu ac mi cursus elementum neque. Massa nisl fringilla platea diam faucibus nullam. In lacus mauris nec ultrices. Ut accumsan leo adipiscing montes proin.

Polly standardizes biomedical data by applying rigorous curation and metadata enrichment. It delivers harmonized, high-quality datasets, ensuring accuracy, consistency, and seamless AI/ML integration for better target prediction.

What role does robust data play in reducing clinical trial failures?

Lorem ipsum dolor sit amet consectetur. Dictumst faucibus nibh imperdiet phasellus vitae ut sit. Ut eros amet massa tellus orci. Vestibulum ac arcu est nulla non eget nulla. Eget pulvinar eu ac mi cursus elementum neque. Massa nisl fringilla platea diam faucibus nullam. In lacus mauris nec ultrices. Ut accumsan leo adipiscing montes proin.

Robust, harmonized data improves target selection, reducing clinical trial failures. Polly provides clean, well-structured datasets, leading to better predictions, lower false discovery rates, and higher clinical success.

How can Polly help expand the pipeline of validated targets?

Lorem ipsum dolor sit amet consectetur. Dictumst faucibus nibh imperdiet phasellus vitae ut sit. Ut eros amet massa tellus orci. Vestibulum ac arcu est nulla non eget nulla. Eget pulvinar eu ac mi cursus elementum neque. Massa nisl fringilla platea diam faucibus nullam. In lacus mauris nec ultrices. Ut accumsan leo adipiscing montes proin.

Polly accelerates validated target discovery by enabling researchers to create disease-specific multi-omics atlases. These ML-ready datasets enhance prediction accuracy and streamline drug development.

What are the benefits of using clean and integrated data for target selection?

Lorem ipsum dolor sit amet consectetur. Dictumst faucibus nibh imperdiet phasellus vitae ut sit. Ut eros amet massa tellus orci. Vestibulum ac arcu est nulla non eget nulla. Eget pulvinar eu ac mi cursus elementum neque. Massa nisl fringilla platea diam faucibus nullam. In lacus mauris nec ultrices. Ut accumsan leo adipiscing montes proin.

Clean, integrated biomedical data improves prediction accuracy, minimizes biases, and enhances biomarker discovery. Polly’s harmonized datasets drive more confident decision-making, reducing false leads, and accelerating therapeutic advancements.

Request Demo